The following is a summary of “Effect of sarcopenia on prognosis in patients with mild acute ischemic stroke: a prospective ...

Stroke is the number one cause of adult disability in the United States. The most common type of stroke is ischemic (non-bleeding), which occurs when there is sudden loss of blood flow to an area of ...

In the US, the rate of ischemic stroke among adults aged 20 to 44 surged from 17 per 100,000 adults in 1993 to 28 per 100,000 in 2015. The risk of stroke death among young adults is also on the rise.

just like an ischemic stroke. The difference is that the blockage is short-lived and generally lasts less than an hour. By definition, symptoms should resolve within 24 hours. However, a TIA can ...

Tenecteplase provides comparable safety and effectiveness outcomes for acute ischemic stroke as alteplase, new research ...

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according to the manufacturer. Genentech said in a press release that TNKase ...

Recombinant human prourokinase is noninferior to alteplase in acute ischemic stroke, with symptomatic intracranial hemorrhage and major bleeding decreased.

The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults. TNKase is delivered as a ...

The US Food and Drug Administration has approved the thrombolytic tenecteplase for the treatment of patients with acute ischemic stroke, manufacturer Genentech announced today. The approval is based ...